Login to Your Account



Lipid Therapeutics Extends Colitis Program to U.S.

By Cormac Sheridan
Staff Writer

Wednesday, April 17, 2013
Lipid Therapeutics GmbH aims to extend its pivotal program for its ulcerative colitis treatment LT-02 into the U.S., following an investigational new drug grant from the FDA that will enable it and its partner, Dr. Falk Pharma GmbH, to conduct a joint Phase III program on either side of the Atlantic. The plan depends on the company finding a U.S. partner, however.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription